Novel evaluation of the expression patterns CD44 and MMP9 proteins in intracranial meningiomas and their relationship to the overall survival

doi:10.21203/rs.3.rs-1495159/v1

Download PDF

Research Article

Novel evaluation of the expression patterns CD44 and MMP9 proteins in intracranial meningiomas and their relationship to the overall survival

https://doi.org/10.21203/rs.3.rs-1495159/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Background

Meningiomas are common primary brain neoplasms. CD44 is a cell surface glycoprotein receptor that is involved in matrix-mediated cell signaling and cell-matrix adhesion. Matrix metalloproteinase-9 (MMP-9) plays important role in angiogenesis and tumor invasion. The expression of CD44 protein membranous and cytoplasmic (CD44M and CD44C) has been reported in several tumors (such as lobular carcinoma, renal cell carcinoma, sinonasal melanoma and lymphoma) except CNS tumor.

Methods

This study addressed the expression CD44M and CD44C and MMP9 proteins in intracranial meningiomas and their relationship to overall survival. The expression patterns of CD44M&C and MMP-9 proteins were examined in 32 cases of benign meningiomas, 12 cases of atypical meningiomas, and 6 cases of anaplastic meningiomas using immunohistochemical staining methods.

Results

There was more evident of CD44M expression in atypical and anaplastic meningioma (p = < 0.001). Interestingly, Spearman correlation analyses revealed significant positive correlation between CD44M and MMP9 protein (r = 0.572, p = < 0.001) in spite of there was negative correlation between MMP9 and CD44 score (r= -0.035 p = 0.405). There was a significant association between Ki67 protein expression and the grade of meningiomas (p < 0.001) and gender (p = 0.026). There was a significant correlation between overall survival (OS) and age, gender, tumor grade and Ki67.

Conclusions

Extensive CD44M expression in high-grade meningioma may reflect a tendency toward more invasive power of meningioma cells into surrounding structures (dura, bone and brain).CD44M/MMP-9 axis presented by this study are open for future investigations.

CD44

MMP9

Ki67

Meningiomas

Meningioma is one of the most common primary brain neoplasms, accounting for nearly 30% of all central nervous system tumors ^{[1, 2]}. Meningioma is thought to originate from the arachnoid cap cells of the leptomeninges. The meningioma according to World Health Organization (WHO) 2016 classification of central nervous system tumors graded from I to III. Recently brain invasion considered as criterion for diagnosis of atypical meningioma ^{[1, 2]}. Mostly grade I meningioma characterized by benign behavior in contrast to grade II/III meningiomas have had a poor prognosis. ^{[3, 4]}

CD44 is a cell surface glycoprotein receptor which is ligand to hyaluronan; an extracellular matrix molecule, being implicated in matrix mediated cell signaling and in cell-matrix adhesion. It is expressed on almost all human cells. It is important for regulating of cell adhesion, migration, angiogenesis, proliferation and inflammation ^[5]. CD44 is assumed to be related to tumour invasion and metastatic ability. It was studied on several tumours types, including meningiomas ^[6]. The expression of CD44 protein (membranous and cytoplasmic expression) has been reported in several tumors such as infiltrating lobular carcinoma ^[7], renal cell carcinoma ^[8], sinonasal melanoma ^[9] and lymphoma ^[10].

Matrix metalloproteinases (MMPs) are proteolytic enzymes that degrade extracellular matrix components and take part in normal physiological processes of tissue remodeling. MMP-9 has been assigned an important role during angiogenesis and tumor invasion ^[11]. MMP expression in meningiomas has been studied in relation to tumor invasiveness, malignancy, or recurrence ^{[12, 13]}.

A major issue relates to the recurrence of totally resected (Simpson’s grade I) meningiomas and to the identification of its predicting factors. Indeed, despite total macroscopic resection of meningiomas, relapses do occur, although the reasons for this phenomenon are still not fully clarified. It has been suggested that the recurrence of totally resected (Simpson’s grade 1) meningiomas may be related to the presence of microscopic clusters of neoplastic cells left in the dura mater or in the arachnoid membrane ^{[14, 15]}.

Expression of CD44 in meningioma patients with intracranial meningiomas is still controversial. Few studies demonstrated marked expression in high grade meningiomas ^{[16, 17]}, in contrast to another conclude that the expression is more extensive in benign meningioma than atypical meningioma ^{[18, 19]}. Concerning MMP-9, authors have reported on parallel increase in MMP-9 expression in high grade meningioma compared to benign meningioma ^{[20, 21]}.

To date, there is no data detailing the pattern of expression of CD44 (CD44 M&C) in meningiomas and its relationship to MMP-9. To the best of our knowledge, the present report is the first to investigate the correlation between CD44 M&C expression pattern and MMP-9 in intracranial meningiomas and their relationship to OS.

a) Patients and tumor samples:

This retrospective study was carried out at the Pathology Department, Faculty of Medicine, Al-Azhar University (Assuit branch, Assuit, Egypt) in the period between April 2015 and June 2020. The patients were followed up until May 2020. The specimens included paraffin-embedded tumor blocks representing 32 cases of benign meningiomas, 12 cases of atypical meningiomas, and 6 cases of anaplastic meningiomas. The Hematoxylin and Eosin-stained slides were initially and independently reviewed by two neuropathologists, without prior knowledge of the clinical data. The histopathological diagnoses were rendered according to the revised WHO 2016 classification criteria of CNS tumors using standard histological criteria ^[2]. The demographic and clinical data were obtained retrospectively from chart review files of the Neurosurgery Departments, Assiut University and South Valley University. Patient confidentiality was strictly maintained throughout this study. The patients have given written consent at the date of surgical operation for the use of their tissue within these studies. The study was reviewed and approved by the local ethics committee of Assiut University.

b) Immunohistochemistry:

Formalin-fixed paraffin-embedded (FFPE) slides from the meningiomas tissue blocks, were retrieved from pathology lab and included for IHC study. The FFPE blocks were cut into 3–4-μm thickness, and then put on positively charged glass slides. Sections were de-paraffinized and rehydrated, followed by antigen retrieval, which was done with Tris-EDTA in a water bath at 90°C for 45 minutes. The primary Mouse Anti-Human CD44 Std. Clone SPM521, Dilution 1:100) (CATALOG #: E17361, Spring bioscience, Pleasanton, California, USA).

Ki-67 primary mononclonal mouse antibody (clone MIB-1) (Code Number: M7240, Dilution 1:50 Dako), and Mouse monoclonal antibody against human MMP9 (CloneVIIC2; Dilution 1:100, Lab Vision Corp., Freemont, California, USA) were applied. Each incubated for one hour at room temperature. A universal staining kit “Ultra Vision Detection System Anti-Polyvalent, HRP/DAB (ready-to-use)” (catalog #TP-015-HD, LAB VISION Corp., Fremont, CA, USA) was applied following the manufacturer’s instructions. The sections were then counterstained with Mayer’s Hematoxylin. The immunostaining was performed using appropriate positive and negative controls. Replacement of the primary antibody with a blocking buffer was used to generate negative control slides.

c) Evaluation of CD44, MMP9 and Ki67 expression:

A general assessment was made of the expression pattern, taking into account the location particularly for CD44 (cytoplasm and/or cell membrane) and the amount of positivity detected.

Staining scores for MMP-9 and CD44 were established semi-quantitatively as described by Okada et al.2004 [21] Specifically, immunohistochemical score for each antibody was calculated by optical analysis using the sum of the percentage of positive cells (0: none; 1: 1–30%; 2: 31–60%; 3: 61–100%) and staining intensity graded from 1 to 3 (1, weak; 2, moderate; and 3, strong). The scores were determined by concordance among the scores of two independent reviewers unaware of the clinico-pathological data. From a statistical point of view immunohistochemical scores of 4 or greater were considered to represent high expression, and those of 3 or lower to indicate low expression. Evaluation of Ki67 was performed under a high-power objective (magnification 400×), and distinct nuclear staining was recorded as positive.

The areas with the highest number of positive tumor nuclei (hot spots) were selected and an average of 1000 tumor cells from the areas of maximum labeling were counted for analysis ^[22]. A Ki-67 value of 4% was used as a cut-off point to determine low and high Ki-67 expression, as suggested by Perry et al.1998 ^[23].

Statistical Analysis

The collected data were verified, coded by the researcher and analyzed using the Statistical Package for Social Sciences (IBM-SPSS/PC/VER 21). Descriptive statistics: mean, standard deviation, median, range, frequencies, percentage were calculated. Test of significances: Chi square and Fisher Exact tests were used to compare the difference in distribution of frequencies among different groups. Student t-test and Mann-Whitney U test were calculated to test the mean differences in continuous variables between groups (parametric and non-parametric). The Kaplan-Meier method was used to analyze survival, and the log-rank test was used to estimate differences in survival. Multivariate Cox Hazard regression analysis was calculated to investigate the significant factors influencing OS (Hazard Ratio -HR-, 95% confidence interval -95% CI-). Correlation analysis was used to test the association between variables (Spearman’s rank correlation). A significant p value was considered when it was less than 0.05.

Clinicopathological Characteristics

The current study included 50 patients (9 male and 41 female patients) with intracranial meningioma of various grades: 32 benign (GI) and 12 atypical (GII) and 6 anaplastic (GIII). In the group of benign meningiomas, 18 were meningothelial, 8 fibroblastic, 2 psammomatous, 2 microcystic and 2 angiomatous.

The patients’ age ranged from 17 – 67 years with a mean age of 50.22±12.56. For statistical purpose the studied cases were divided into two groups 32 benign (GI) meningiomas and 18 atypical and anaplastic meningiomas (GII/GIII).

Complete excision, including dura and bone (Simpson grade 1), had been performed in 10/50 meningiomas (20%). Complete excision plus apparently reliable coagulation of dural attachments (Simpson grade 2) had been gained in 36/50 cases (72%). Complete excision of the solid tumor, but with insufficient dural coagulation or bone excision (Simpson grade 3), had been performed in 2/50 cases (4%).Tumor biopsy (Simpson grade 4) had been gained in 2/50 (4%).

Four patients had died of their tumor during the follow-up period. The median OS of these patients was 4.9 years (range: 3.95-4.93) using Kaplan-Meier estimates. The clinical characteristics of the patients are listed in Table 1

Table (1) Clinical characteristics of patients with intracranial meningiomas:

Histological type	Number (%)	Age (mean±SD)	Sex (No/%)		Simpson grade				OS
Histological type	Number (%)	Age (mean±SD)	Male	Female	I	II	III	IV	Alive	Dead
Benign (GI)	32	54.19±9.55	4(12.5)	28(87.5)	8(25.0)	22(8.8)	----	2(6.3)	32	0
Meningothelial	18(36.0)	55.67±9	2 (22.2)	16 (39.0)	6 (60.0 )	12 (33.3)	----	0.0
Fibroblastic	8(16.0)	53.25±10.38	2 (22.2)	6 ( 14.6)	2 (20.0)	4 (11.1)	-----	2(100.0)
Microcystic	2 (4.0)	45±0	0 (0.0)	2 ( 4.9)	0.0	2 (5.6)	------	0.0
Psammomatous	2(4.0)	65±0	0 (0.0)	2 (4.9)	0.0	2 (5.6)	------	0.0
Angiomatous	2(4.0)	43±0	0 (0.0)	2 (4.9)	0.0	2 (5.6)	------	0.0
Atypical (GII)	12	38.5±15.17	2(16.7)	10(83.3)	2 (20.0)	8 (22.2)	2(100.0)	0.0	10	2
Anaplastic (GIII)	6 (12%)	52.5±6.02	3(50.0)	3(50.0)	0 (0.0)	6 (16.7)	0(0.0)	0.0	4	2

Association between immunohistochemical markers and clinicopathological parameter.

All cases of meningiomas express the CD44 (Cytoplasmic and/or membranous), cytoplasmic MMP-9 and nuclear Ki-67.

CD44 expression:

The mean of CD44 score was 3.38±0.87 of benign (GI) and 4.67 ± 0.8 for atypical and anaplastic meningiomas (GII/III). There was significant association between CD44scores and different grades (I vs II/III; Figuer1A-C) of meningiomas (p= <0.001) and Simpson grade (p=0.026). Table2

Table 2: Summary of Clinicopathological Data of Meningioma Patients

Parameter	No.	CD44			MMP-9			Ki-67%
Parameter	No.	Mean ± SD	Median (IQR)	P-value	Mean ± SD	Median (IQR)	P-value	Mean ± SD	Median (IQR)	P-value
Age Group
< 50 years	24	3.83 ± 1.1	4 (2)	= 0.935	4.50 ± 1.6	5 (3)	= 0.261	8.45 ± 7.9	6 (5)	= 0.115
≥ 50 years	26	3.85 ± 1.1	4 (1)	= 0.935	4.04 ± 1.6	4 (2)	= 0.261	5.51 ± 4.8	4 (4)	= 0.115
Sex
Female	41	3.80 ± 1.1	4 (2)	= 0.356	4.20 ± 1.5	5 (3)	= 0.402	6.55 ± 6.2	5 (5)	= 0.026
Male	9	4.00 ± 0.7	4 (1)	= 0.356	4.56 ± 1.9	5 (2)	= 0.402	8.60 ± 6.1	13 (11)	= 0.026
Grade
G I	32	3.38 ± 0.9	3 (1)	< 0.001	3.81 ± 1.5	4 (2)	< 0.001	3.28 ± 2.2	3 (3)	< 0.001
G II-III	18	4.67 ± 0.8	4 (1)	< 0.001	5.06 ± 1.4	5.5 (1)	< 0.001	13.89 ± 6.8	14 (10)	< 0.001
Simpson Grade
I	10	3.40 ± 1.4	3 (1)	=0.026**	3.80 ± 1.9	3.5 (2)	= 0.527	7.80 ± 6.7	3 (3)	= 0.845
II	36	3.89 ± 1.0	4 (1)		4.42 ± 1.5	5 (3)		6.58 ± 5.4	6 (5.5)
III-IV	4	4.50 ± 0.6	4.5 (1)		4.00 ± 1.2	4 (2)		7.80 ± 5.2	8 (7)

Expression pattern of CD44 (Cytoplasmic and/or membranous) was evaluated in all studied meningiomas. Within those with of benign (GI) meningiomas 20/32 (62.5%) express the membranous pattern, however 10/12 (83.3%) and 6/6 of atypical and anaplastic express the membranous pattern, respectively (Figure 2 A&B). The differences in the expression pattern between different grades of meningiomas were statistically significant (P= <0.001). The details of expression pattern of CD44 are listed in Table 3.

Table 3: The CD44 protein expression patterns in intracranial meningiomas.

	Types						P. value
	Benign (n=32)		Atypical (n=12)		Anaplastic (n=6)		P. value

CD44C*
-	0	0.0	0	0.0	3	50.0	<0.001**
+	16	50.0	2	16.7	0	0.0
++	4	12.5	2	16.7	3	50.0
+++	12	37.5	8	66.7	0	0.0
CD44M*
-	12	37.5	2	16.7	0	0.0	<0.001**
+	14	43.8	8	66.7	0	0.0
++	6	18.8	2	16.7	3	50.0
+++	0	0.0	0	0.0	3	50.0

MMP-9 expression;

The mean of MMP-9 score of benign (GI) meningiomas were 3.81 ± 1.5, while atypical and anaplastic meningiomas (GII/III) were 5.06 ± 1.4. There was significant association between MMP-9 scores and pathological grades of meningiomas (P< 0.001; Figure 1 D-F). There was no significant correlation between MMP-9 and other clinicopathological variables (Table 2).

Ki-67 Expression;

The mean of Ki67 score within benign meningiomas (GI) were 3.28 ± 2.2, of atypical and anaplastic meningiomas (GII/III) was 12.08%±8%. Ki67 expression showed significant association with meningiomas grade (P<0.001; Figure 1 G-I) and gender (p=0.026). (Table2)

Correlation between the immunohistochemical markers:

Significant positive correlation was noted between Ki-67 and CD44 score, Ki-67 and MMP-9, CD44 membranous expression and MMP-9 (r=0.263, p =0.032), (r=0.256 p=0.037), (r=0.572, p= <0.001), respectively. Interestingly, however there was negative correlation between MMP9 and CD44 score (r= -0.035 p=0.405), there was positive correlation between MMP9 and CD44 membranous expression (r=0.242, p=0.045). The details of Spearman’s correlation between immunohistochemical markers are listed in Table 4.

Table 4: The correlation among the expression values of Ki67, CD44, and MMP9 protein expression in intracranial meningiomas.

Parameter	Ki67	MMP9	CD44 Score
Parameter	rho* (P-value)
Total (n=50)
CD44 Score	0.263 (=0.032)	-0.035 (=0.405)	1
CD44-Cytoplasmic	0.036 (=0.402)	-0.257 (=0.036)	1
CD44-Membranous	0.572 (<0.001)	0.242 (=0.045)	1
MMP9	0.256 (=0.037)	1	-0.035 (=0.405)

*Spearman's Ranked Correlation Coefficient.

Survival Analyses

Overall survivals were analyzed by the expression of each immunohistochemical markers, age, gender, tumor grade and Simpson grade (II-IV). On univariate analysis , significant correlation was found between OS and age group (≥ 50 years), gender (male) and Grade II/III (p=0.041,p=0.012,p=0.014) respectively.

The expression of immunohistochemical markers (CD44 and MMP9) did not correlate with OS, however Ki67 showed statistically significant correlation with OS (OS: HR, 1.136 95% confidence interval (CI) 1.025-1.259, p=0.015).

On multivariate analysis, still age, GII/III and Ki-67 significantly correlated with OS (p= 0.046, p= 0.047, p= 0.048), respectively. Additionally, CD44 score and CD44 cytoplasmic was associated with poor OS (OS: HR, 1.881 95% confidence interval (CI) 1.121-4.123, p= 0.044) (OS: HR, 2.401 95% confidence interval (CI), 1.095-5.446, p= 0.046) respectively. The details of univariate correlation and multivariate analysis are listed in Table 5.

Table 5: Cox Proportional Hazard Regression analysis for overall survival in patients with intracranial meningiomas.

Variable	Univariate		Multivariate
Variable	HR (95% CI) *	P-value	HR (95% CI)	P-value
Age Group (≥ 50 years)	1.784 (1.024-2.927)	= 0.041	1.143 (1.011-3.154)	= 0.046
Sex (Male)	4.713 (1.664-8.479)	= 0.012
Grade (GII-III)	5.725 (1.422-9.046)	= 0.014	3.197 (1.055-6.201)	= 0.047
Ki67%	1.136 (1.025-1.259)	= 0.015	1.095 (1.025-1.259)	= 0.048
CD44 score	1.765 (0.723-4.306)	= 0.212	1.881 (1.121-4.123)	= 0.044
CD44 (Cytoplasmic)	1.993 (0.591-6.728)	= 0.266	2.401 (1.095-5.446)	= 0.046
CD44 (Membranous)	1.758 (0.612-5.051)	= 0.294	1.212 (0.702-7.811)	= 0.425
MMP9	1.471 (0.661-3.272)	= 0.344
Simpson Grade II-IV	1.209 (0.488-5.085)	= 0.495

OS: overall survival. *HR, Hazard Ratio; CI, Confidence Interval

According to Kaplan-Meier curve showed significant correlation between median OS and age (≥ 50 years; P=0.031), histological grade (GII/III; p=0.005), and nearly significant for Ki-67 (≥4 cutoff point; p=0.068). Interestingly, CD44 cytoplasmic revealed poor OS (p=0.048), however no association was found between median survival and CD44 membranous (Figure 4).

To the best of this author’s knowledge, the expression patterns of CD44, MMP-9 proteins, and Ki-67 proliferation marker in meningiomas are poorly understood. Moreover, the correlations among these expression patterns and the clinicopathologic features of meningiomas have not been fully addressed by the previous studies. The current study examined the correlation between CD44M&C, MMP-9, and Ki-67 protein expression and the clinicopathological variables (histopathological grades of meningiomas, age, gender, and Simpson grade) and the overall survival of the patients.

In agreement with other investigations, this study revealed overexpression of CD44 protein in atypical and anaplastic meningiomas as compared to their benign counterparts ^{[16, 17]}. In the current study, most cases showed both CD44 cytoplasmic and membranous protein expression patterns, however, the membranous expression was more evident in atypical and anaplastic meningiomas. These findings concur with the previous studies that reported diffuse strong membranous staining in atypical and high-grade meningiomas (II/III) meningiomas ^{[17, 24]}.

Interestingly, some studies reported a decline in CD44 expression in high-grade meningiomas ^{[18, 19]}. Freitag et al 2017^[26] reported a significantly high expression of CD44 mRNA in low-grade tumors than in high-grade meningiomas. This discrepancy between CD44 results in the literature may be reasoned to several possibilities. Importantly, the heterogeneity of CD44 proteins in meningiomas is secondary to its post-translational modifications and differential splicing ^[27]. Also, the variability in the scoring methodologies among the different studies explains this discrepancy.

This current study revealed on multivariate analysis and Kaplan Meier that the CD44 cytoplasmic expression was a poor prognostic factor. In contrast, Kamamoto et al 2018 [17] reported the lack of correlation between CD44 and overall survival, however found a correlation with PFS. This discrepancy may be reasoned to the use of different staining methodologies or study groups.

CD44 is a transmembrane protein, so the delocalization of CD44 to the cytoplasm may cause alterations in the cell-cell and cell-extracellular matrix interactions. Accordingly, cytoplasmic staining in this series may reflect the production of aberrant CD44 proteins by the malignant cells ^[9]. Taken as a whole, this current study and the previous investigations indicate some differences in biological function and timing of expression of the membranous and cytoplasmic of CD44, according to the degree of invasion, i.e., stage-dependent manner).

Interestingly, the grading of meningiomas depends mainly on the invasion of adjacent structures (brain). Taken together, extensive CD44 membranous expression in high-grade meningioma may reflect a tendency toward more invasive power of neoplastic cells into surrounding structures (dura, bone and brain). These findings strengthen the putative role of membranous CD44 protein in the cellular progression of meningiomas.

The pathogenetic roles of CD44 in the development of atypical and high-grade meningiomas may be reasoned to increased motility of the malignant cells and alterations in the cell adhesion ^{[28, 17]}. Several experimental leads support these notions. For instance, the loss of the membranous CD44 protein expression in sinonasal melanomas is associated with increased motility of the melanoma cells resulting from the loss of cellular adhesion ^[28]. Additionally, the cell adhesion by CD44 is predominantly mediated through the extracellular domain, while co-localization of the cytoplasmic domain of CD44 with cytoskeletal proteins, particularly actin, stabilizes the interactions with the substrate ^[29]. Moreover, the overexpression of membranous CD44 protein in the invasive lobular carcinoma was significantly more often observed in lymph node-negative patients than in patients with lymph node metastases ^[7].

The overexpression of MMP-9 protein in the atypical and high-grade meningiomas in the current study is in agreement with the previous investigations ^{[12, 31]}. MMP-9 protein belongs to a family of gelatinases that degrades the extracellular matrix and the basal lamina components such as collagen IV, fibronectin, and laminin ^[30]. Interestingly, some studies ^{[12, 31]} showed a significant correlation between high MMP-9 expression and high histological grade in tumors. Also, an association between the MMP-9 mRNA level and the degree of brain invasion has been reported ^[32]. When the impact of MMP-9 on survival was examined, we did not find any correlation between them. This finding is reasoned to the paucity of the absence of recurrence in the patients included in the study. To the best of our knowledge, only Barresi et al, 2011 ^[12] and Okada et al 2004 ^[21] reported high MMP-9 expression as a prognostic independent variable on multivariate analysis.

To the best of this author’s knowledge, the correlation between CD44 and MMP-9 proteins in meningiomas has not been addressed by the previous studies. Here, this study reports a positive correlation between MMP-9 protein and membranous CD44 protein expression.

Alternatively, a negative correlation with CD44 protein expression (the expression score and the cytoplasmic staining pattern) was detected. Our results are in agreement with findings in other tumors such as malignant melanoma ^[33], prostatic carcinoma ^[34] and mammary carcinoma ^[35]. Gupta et al 2013^[36] reported that cell surface interaction of CD44 and MMP-9 proteins increase the migration and the invasion of PC3 cells. In contrast, Lee et al 2019 demonstrated a correlation between CD 44 and MMP9 proteins in clear RCC, who did not found this correlation in non-clear renal cell carcinoma. The discrepancy among the different studies concerning the relationship between CD44 and MMP-9 protein expression may be explained in the light of findings reported by Desai et al 2009 ^[38]. Desai and his colleagues indicated a decrease in the surface expression of CD44 in the prostate cancer cell (PC3) knock-down of MMP-9 and a decrease in the activation of MMP-9 in cells null for CD44 ^[38]. In addition, downregulation of MMP-9 protein expression in PC3 cells switches CD44 isoform expression from CD44s to CD44v6 which is more glycosylated. ^[36]

Taken together, the correlation of MMP-9 and CD44 protein expression depends mainly on the pattern of membranous expression more than on the cellular level of CD44 protein, whether CD44 is linked with MMP-9 proteins at the surface of the cell in intracranial meningiomas. CD44M/MMP-9 axis in atypical and anaplastic meningiomas may be at the basis of the higher invasive potential towards the brain parenchyma and bone of these neoplasias. ^{[33, 36, 38]}

The results of the current study are in line with the previous investigations that demonstrated the correlation between meningioma grade and the Ki-67 labeling indices. Moreover, Ki67 labeling indices were the most important independent prognostic parameters in high-grade meningiomas ^[40]. In agreement with other studies, this study revealed a significant positive correlation among the indices of the proliferative marker Ki-67 and CD44 ^{[16, 19]} and MMP-9 proteins expression values ^{[12, 41]} protein expression. In contrast, Barresi et al 2012^[12] and Okada et al 2004 ^[21] did not find any correlations between Ki-67 and MMP-9 protein expression. This discrepancy probably reflects the small sample size of the study groups (only three cases of atypical meningioma) and the use of different cut off points for scoring Ki-67 labeling index. ^{[12, 21]}

Our work demonstrated statistically significant high expression of CD44, MMP-9, and Ki-67 scores in high-grade meningiomas. Our findings demonstrate, for the first time, a positive correlation between CD44M and MMP-9 protein expression in meningiomas. Our study revealed that the CD44 cytoplasmic is a poor prognostic factor. (p < 0.001). Accordingly, CD44M/MMP-9 protein axis was a promising biomarker for meningiomas prognosis prediction and therapeutic implication. Expression of CD44 membranous and cytoplasmic require quantitative and qualitative assessment and their relationship to MMP-9, OS, and PFS on large-scale studies to further validate our results in the future.

MMP

Matrix metalloproteinase.

WHO

World Health Organization.

MRI

Magnetic resonance imaging.

FFPE

Formalin-fixed paraffin-embedded.

overall survival.

hazard ratio.

confidence interval.

Ethics approval and consent to participate.

Patient confidentiality was strictly maintained throughout this study. The patients have given written consent at the date of surgical operation for the use of their tissue within these studies. The study was reviewed and approved by the local ethics committee of Assiut University.

Consent for publication

A written consent has been obtained from every included patients regarding publishing their details and images.

Availability of data and material

The data and materials of this manuscript are available for sharing.

Competing interests

There is no conflict of interest on this manuscript.

Funding

No available fund (This research was funded by the authors).

Authors' contributions

"All authors have read and approved the manuscript"

‘AA’: Conception and design of study, drafting of article, analysis and interpretation of data, and final approval of the version to be published.

‘AE’: Shared in putting study design, collection of data, analysis and interpretation of data, writing the manuscript, and final approval of the version to be published

‘RK’: Shared in putting study design, writing the manuscript, and final approval of the version to be published

‘AH’: Shared in putting study design, collection of data, analysis and interpretation of data, writing the manuscript, and final approval of the version to be published.

Acknowledgements

'Not applicable'

Unteroberdörster M, Michel A, Darkwah Oppong M, Jabbarli R, Hindy NE, Wrede KH, Sure U, Pierscianek D. The 2016 Edition of the WHO Classification of Primary Brain Tumors: Applicable to Assess Individual Risk of Recurrence in Atypical Meningioma? A Single-Center Experience. J Neurol Surg A Cent Eur Neurosurg. 2021 Apr 12. doi: 10.1055/s-0040-1720987. Epub ahead of print. PMID: 33845510.
Louis D, Ohgaki H, Wiestler O, Cavenee WK. WHO Classification of Tumours of the Central Nervous System, Revised. 4th ed. Lyon, France: IARC Press; 2016.
Durand A, Labrousse F, Jouvet A, et al. WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol. 2009; 95:367–375.
Zhao P, Hu M, Zhao M, Ren X, Jiang Z. Prognostic factors for patients with atypical or malignant meningiomas treated at a single center. Neurosurg Rev. 2015; 38:101–107.
Naruse M, Shibasaki K, Yokoyama S, Kurachi M, Ishizaki Y. Dynamic changes of CD44 expression from progenitors to subpopulations of astrocytes and neurons in developing cerebellum. PLoS One. 2013; 8(1):e53109.
Rooprai HK, Liyanage K, King A, Davies D, Martin K, Pilkington GJ. CD44 expression in human meningiomas: An immunocytochemical, immunohistochemically and flow cytometric analysis. Int J Oncol. 1999 May; 14(5):855 – 60. doi: 10.3892/ijo.14.5.855. PMID: 10200334
Berner HS, Nesland JM. Expression of CD44 isoforms in infiltrating lobular carcinoma of the breast. Breast Cancer Res Treat. 2001 Jan; 65(1):23 – 9. doi: 10.1023/a:1006417412046. PMID: 11245336.
Lee YM, Kim JM, Lee HJ, Seong IO, Kim KH. Immunohistochemical expression of CD44, matrix metalloproteinase2 and matrix metalloproteinase9 in renal cell carcinomas. Urol Oncol. 2019 Oct; 37(10):742–748. doi: 10.1016/j.urolonc.2019.04.017. Epub 2019 Apr 30. PMID: 31053527.
Regauer S, Ott A, Berghold A, Beham A. CD44 expression in sinonasal melanomas: is loss of isoform expression associated with advanced tumour stage? J Pathol. 1999 Jan; 187(2):184 – 90. doi: 10.1002/(SICI)1096-9896(199901)187:2<184::AID-PATH216>3.0.CO;2-2. PMID: 10365093.
Lemma SA, Kuusisto M, Haapasaari KM, Sormunen R, Lehtinen T, Klaavuniemi T, Eray M, Jantunen E, Soini Y, Vasala K, Böhm J, Salokorpi N, Koivunen P, Karihtala P, Vuoristo J, Turpeenniemi-Hujanen T, Kuittinen O. Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma. Carcinogenesis. 2017 Aug 1; 38(8):812–820. doi: 10.1093/carcin/bgx061. PMID: 28854563; PMCID: PMC5862348.
Iwado E, Ichikawa T, Kosaka H, Otsuka S, Kambara H, Tamiya T, Kondo S, Date I. Role of VEGF and matrix metalloproteinase-9 in peritumoral brain edema associated with supratentorial benign meningiomas. Neuropathology. 2012 Dec; 32(6):638–46. doi: 10.1111/j.1440-1789.2012.01312.x. Epub 2012 Mar 15. PMID: 22420586.
Barresi V, Vitarelli E, Tuccari G, Barresi G. MMP-9 expression in meningiomas: a prognostic marker for recurrence risk? J Neurooncol. 2011 Apr; 102(2):189–96. doi: 10.1007/s11060-010-0312-8. Epub 2010 Jul 21. PMID: 20652360.
Beltran E, Matiasek K, De Risio L, de Stefani A, Feliu-Pascual AL, Matiasek LA. Expression of MMP-2 and MMP-9 in benign canine rostrotentorial meningiomas is not correlated to the extent of peritumoral edema. Vet Pathol. 2013 Nov; 50(6):1091–8. doi: 10.1177/0300985813481610. Epub 2013 Mar 25. PMID: 23528939.
Kinjo T, al-Mefty O, Kanaan I. Grade zero removal of supratentorial convexity meningiomas. Neurosurgery. 1993 Sep; 33(3):394-9; discussion 399. doi: 10.1227/00006123-199309000-00007. PMID: 8413869.
Kamitani H, Masuzawa H, Kanazawa I, and Kubo T. Recurrence of convexity meningiomas: tumor cells in the arachnoid membrane. Surg Neurol. 2001 Oct; 56(4):228 – 35. doi: 10.1016/s0090-3019(01)00582-1. PMID: 11738666.
Mostafa RR, Khairy RA. CD44 Expression in Meningioma and its Correlation with Proliferation Indices. J Clin Diagn Res. 2017 Aug; 11(8):EC12-EC15. doi: 10.7860/JCDR/2017/28438.10379. Epub 2017 Aug 1. PMID: 28969134; PMCID: PMC5620774
Kamamoto D, Saga I, Ohara K, Yoshida K, Sasaki H. Association Between CD133, CD44, and Nestin Expression and Prognostic Factors in High-Grade Meningioma. World Neurosurg. 2018 Dec 26:S1878-8750(18)32890-0. doi: 10.1016/j.wneu.2018.12.067. Epub ahead of print. PMID: 30593958.
Figarella-Branger D, Roche PH, Daniel L, Dufour H, Bianco N, Pellissier JF. Cell-adhesion molecules in human meningiomas: correlation with clinical and morphological data. Neuropathol Appl Neurobiol. 1997 Apr; 23(2):113–22. PMID: 9160896.
Arsene D, Comănescu M, Ardeleanu C. Adhesion cell molecules as potential markers of aggressiveness in meningiomas. Rom J Morphol Embryol. 2014; 55(2 Suppl):585-9. PMID: 25178329.
Barresi V, Vitarelli E, Tuccari G, Barresi G. MMP-9 expression in meningiomas: a prognostic marker for recurrence risk? J Neurooncol. 2011 Apr; 102(2):189–96. doi: 10.1007/s11060-010-0312-8. Epub 2010 Jul 21. PMID: 20652360.
Okada M, Miyake K, Matsumoto Y, Kawai N, Kunishio K, Nagao S. Matrix metalloproteinase-2 and matrix metalloproteinase-9 expressions correlate with the recurrence of intracranial meningiomas. J Neurooncol. 2004 Jan; 66(1–2):29–37. doi: 10.1023/b:neon.0000013474.01161.58. PMID: 15015767.
Reid MD, Bagci P, Ohike N, Saka B, Erbarut Seven I, Dursun N, Balci S, Gucer H, Jang KT, Tajiri T, Basturk O, Kong SY, Goodman M, Akkas G, Adsay V. Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. Mod Pathol. 2015 May; 28(5):686 – 94. doi: 10.1038/modpathol.2014.156. Epub 2014 Nov 21. Erratum in: Mod Pathol. 2016 Jan; 29(1):93. PMID: 25412850; PMCID: PMC4460192.
Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer. 1998 Jun 1; 82(11):2262–9. PMID: 9610708.
Lewy-Trenda I, Omulecka A, Janczukowicz J, Papierz W. CD44 expression in human meningiomas: an immunohistochemical analysis. Pol J Pathol. 2004; 55(1):33–7. PMID: 15195704.
Gassoum A, Arbab MA, Aldeaf SAH, Elhassan LA, Bashier BM, Saad MSA, et al. CD44 expression in sudanese meningioma patients. International Journal of Recent Scientific Research. 2016; 7(6):11900–04.
Freitag D, McLean AL, Simon M, Koch A, Grube S, Walter J, Kalff R, Ewald C. NANOG overexpression and its correlation with stem cell and differentiation markers in meningiomas of different WHO grades. Mol Carcinog. 2017 Aug; 56(8):1953–1964. doi: 10.1002/mc.22653. Epub 2017 Apr 17. PMID: 28345785.
Cichy J, Pure E. The liberation of CD44. J Cell Biol 2003; 161:839–43. http://dx.doi.org/10.1083/jcb.200302098.
Harwood CA, Green MA, Cook MG. CD44 expression in melanocytic lesions: a marker of malignant progression? Br J Dermatol. 1996 Dec; 135(6):876 – 82. doi: 10.1046/j.1365-2133.1996.d01-1089.x. PMID: 8977706.
Lacy BE, Underhill CB. The hyaluronate receptor is associated with actin filaments. J Cell Biol. 1987 Sep; 105(3):1395–404. doi: 10.1083/jcb.105.3.1395. PMID: 2443509; PMCID: PMC2114800.
von Randow AJ, Schindler S, Tews DS. Expression of extracellular matrix-degrading proteins in classic, atypical, and anaplastic meningiomas. Pathol Res Pract. 2006; 202(5):365–72. doi: 10.1016/j.prp.2006.01.012. Epub 2006 Mar 24. PMID: 16563650.
Reszec J, Hermanowicz A, Rutkowski R, Turek G, Mariak Z, Chyczewski L. Expression of MMP-9 and VEGF in meningiomas and their correlation with peritumoral brain edema. Biomed Res Int. 2015; 2015:646853. doi: 10.1155/2015/646853. Epub 2015 Mar 3. PMID: 25821815; PMCID: PMC4363610.
Nordqvist AC, Smurawa H, Mathiesen T. Expression of matrix metalloproteinases 2 and 9 in meningiomas associated with different degrees of brain invasiveness and edema. J Neurosurg. 2001 Nov; 95(5):839 – 44. doi: 10.3171/jns.2001.95.5.0839. PMID: 11702875.
Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. 1999 Jan 1; 13(1):35–48. doi: 10.1101/gad.13.1.35. PMID: 9887098; PMCID: PMC316376.
Desai B, Rogers MJ, Chellaiah MA. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer. 2007; 6:18.
Joseph C, Alsaleem M, Orah N, Narasimha PL, Miligy IM, Kurozumi S, Ellis IO, Mongan NP, Green AR, Rakha EA. Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival. Breast Cancer Res Treat. 2020 Jul; 182(2):267–282. doi: 10.1007/s10549-020-05670-x. Epub 2020 May 22. PMID: 32445177; PMCID: PMC7297818.
Gupta A, Cao W, Sadashivaiah K, Chen W, Schneider A, Chellaiah MA. Promising noninvasive cellular phenotype in prostate cancer cells knockdown of matrix metalloproteinase 9. ScientificWorldJournal. 2013; 2013:493689. doi: 10.1155/2013/493689. Epub 2013 Feb 6. PMID: 23476138; PMCID: PMC358092
Lee YM, Kim JM, Lee HJ, Seong IO, Kim KH. Immunohistochemical expression of CD44, matrix metalloproteinase2 and matrix metalloproteinase9 in renal cell carcinomas. Urol Oncol. 2019 Oct; 37(10):742–748. doi: 10.1016/j.urolonc.2019.04.017. Epub 2019 Apr 30. PMID: 31053527.
Desai B, Ma T, Zhu J, Chellaiah MA. Characterization of the expression of variant and standard CD44 in prostate cancer cells: identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface. J Cell Biochem. 2009 Sep 1; 108(1):272–84. doi: 10.1002/jcb.22248. PMID: 19582779; PMCID: PMC7198262
Dictor M, Ehinger M, Mertens F, Akervall J, Wennerberg J. Abnormal cell cycle regulation in malignancy. Am J Clin Pathol. 1999 Jul;112(1 Suppl 1):S40-52. PMID: 10396300.
Liu N, Song SY, Jiang JB, Wang TJ, Yan CX. The prognostic role of Ki-67/MIB-1 in meningioma: A systematic review with meta-analysis. Medicine (Baltimore). 2020 Feb;99(9):e18644. doi: 10.1097/MD.0000000000018644. PMID: 32118704; PMCID: PMC7478528.
Panagopoulos AT, Lancellotti CL, Veiga JC, de Aguiar PH, Colquhoun A. Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J Neurooncol. 2008 Aug;89(1):73–87. doi: 10.1007/s11060-008-9588-3. Epub 2008 Apr 17. PMID: 18418552.

No competing interests reported.

Download PDF

Version 1

posted

You are reading this latest preprint version

Novel evaluation of the expression patterns CD44 and MMP9 proteins in intracranial meningiomas and their relationship to the overall survival

Status:

Version 1

Abstract

Background

Methods

Results

Conclusions

Figures

Background

Materials And Methods

Results

Discussion

Conclusion

List Of Abbreviations

Declarations

References

Additional Declarations

Status:

Version 1